article thumbnail

Adcentrx raises funds to advance ADCs into clinical development

Pharmaceutical Technology

Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinical development. Adcentrx Therapeutics is focused on developing protein conjugate therapeutics to treat cancer and other life-threatening diseases.

article thumbnail

First patient dosed in trial of antibody for kidney disease

Drug Discovery World

The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. Semaphorin-3A is an extracellular guidance protein and a well-known regulator of the actin cytoskeleton.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Three trends in the antibody-drug conjugate (ADC) market 

Drug Discovery World

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

article thumbnail

Ono Pharmaceutical enters research deal with Monash University

Pharmaceutical Technology

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). We look forward to working with Ono Pharmaceutical to accelerate treatments across a variety of diseases.”.

Research 130
article thumbnail

FibroGen and Fortis sign exclusive licence deal for mCRPC drug candidate

Pharmaceutical Technology

FibroGen has signed an exclusive licence agreement with Fortis Therapeutics for the FOR46 antibody-drug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene. FOR46 is a natural fit with our research and development capabilities and expertise.

Drugs 130
article thumbnail

New COVID-19 nasal spray outperforms current antibody treatments in mice?

The Pharma Data

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19. “Our minibinders sit on top of the spike protein like a tripod and block all three.

article thumbnail

STRO-002 by Sutro Biopharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Pharmaceutical Technology

STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. It is a monoclonal antibody conjugate that acts by targeting f olate receptor alpha (FolR alpha). Sutro Biopharma owns a manufacturing facility in San Carlos, California.

Antibody 100